Conatus Pharmaceuticals is a biotechnology company focused on the development and commercialization of novel medicines to treat chronic diseases with significant unmet need. The Company's lead in-licensed compound, emricasan, is being developed in collaboration with Novartis for the treatment of patients with NASH-driven chronic liver diseases. In addition, Conatus' lead internally developed compound, CTS-2090, is targeting the treatment of patients with chronic diseases involving inflammasome pathways. Source
No articles found.
InnaMed is developing a comprehensive care management platform. Our team is develo...
InnaMed is developing a comprehensive care mana...
NuVasive is a world leader in minimally invasive, procedurally integrated spine so...
NuVasive is a world leader in minimally invasiv...
BioLife Solutions is the leading developer, manufacturer and supplier of proprieta...
BioLife Solutions is the leading developer, man...
We are a leading science and technology company that delivers life-transforming me...
We are a leading science and technology company...
CASI is a U.S. NASDAQ-listed biopharmaceutical company focused on developing and a...
CASI is a U.S. NASDAQ-listed biopharmaceutical ...
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on develop...
Cara Therapeutics is a clinical-stage biopharma...
We are a clinical stage biopharmaceutical company focused on harnessing powerful b...
We are a clinical stage biopharmaceutical compa...
Join the National Investor Network and get the latest information with your interests in mind.